Colorectal cancer patients with GSTP1 were found to show less positive responses than the GSTP1 deficient patients when treated with 5-fluorouracil (5-FU) or Oxaliplatin highlighting the role played by GSTP1 in drug resistance[154]. This evidence concerns the gene GSTP1 and colorectal cancer.